Pharmacoeconomic Model Considers Cost-Effectiveness of Testing UGT1A1 to Dose Irinotecan

Testing colorectal cancer patients for their UGT1A1*28 status before prescribing irinotecan is cost-effective only when reduced doses of the drug are as effective as full doses in patients who are homozygous for the variant.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register quickly here.